vs
Apellis Pharmaceuticals, Inc.（APLS）与Wheels Up Experience Inc.（UP）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Wheels Up Experience Inc.的1.1倍（$199.9M vs $183.8M），Wheels Up Experience Inc.净利率更高（-15.7% vs -29.5%，领先13.8%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -10.2%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-58.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -3.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Wheels Up是美国领先的按需私人航空服务提供商，也是全球规模最大的私人航空企业之一。公司由肯尼·迪希特创立于2013年，采用会员制按需服务的商业模式，会员可通过移动应用程序，从公司自有机队及第三方运营商处预订私人飞机出行。
APLS vs UP — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $183.8M |
| 净利润 | $-59.0M | $-28.9M |
| 毛利率 | — | 14.3% |
| 营业利润率 | -25.6% | -0.9% |
| 净利率 | -29.5% | -15.7% |
| 营收同比 | -5.9% | -10.2% |
| 净利润同比 | -62.2% | 67.0% |
| 每股收益（稀释后） | $-0.40 | $-0.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $183.8M | ||
| Q3 25 | $458.6M | $185.5M | ||
| Q2 25 | $178.5M | $189.6M | ||
| Q1 25 | $166.8M | $177.5M | ||
| Q4 24 | $212.5M | $204.8M | ||
| Q3 24 | $196.8M | $193.9M | ||
| Q2 24 | $199.7M | $196.3M | ||
| Q1 24 | $172.3M | $197.1M |
| Q4 25 | $-59.0M | $-28.9M | ||
| Q3 25 | $215.7M | $-83.7M | ||
| Q2 25 | $-42.2M | $-82.3M | ||
| Q1 25 | $-92.2M | $-99.3M | ||
| Q4 24 | $-36.4M | $-87.5M | ||
| Q3 24 | $-57.4M | $-57.7M | ||
| Q2 24 | $-37.7M | $-97.0M | ||
| Q1 24 | $-66.4M | $-97.4M |
| Q4 25 | — | 14.3% | ||
| Q3 25 | — | 6.8% | ||
| Q2 25 | — | 8.3% | ||
| Q1 25 | — | 10.8% | ||
| Q4 24 | — | 13.9% | ||
| Q3 24 | — | 13.9% | ||
| Q2 24 | — | 2.3% | ||
| Q1 24 | — | -0.6% |
| Q4 25 | -25.6% | -0.9% | ||
| Q3 25 | 48.7% | -33.1% | ||
| Q2 25 | -18.6% | -31.4% | ||
| Q1 25 | -50.0% | -45.5% | ||
| Q4 24 | -12.3% | -26.0% | ||
| Q3 24 | -24.0% | -21.6% | ||
| Q2 24 | -14.7% | -40.3% | ||
| Q1 24 | -36.0% | -42.9% |
| Q4 25 | -29.5% | -15.7% | ||
| Q3 25 | 47.0% | -45.1% | ||
| Q2 25 | -23.6% | -43.4% | ||
| Q1 25 | -55.3% | -55.9% | ||
| Q4 24 | -17.1% | -42.7% | ||
| Q3 24 | -29.2% | -29.8% | ||
| Q2 24 | -18.9% | -49.4% | ||
| Q1 24 | -38.5% | -49.4% |
| Q4 25 | $-0.40 | $-0.04 | ||
| Q3 25 | $1.67 | $-0.12 | ||
| Q2 25 | $-0.33 | $-0.12 | ||
| Q1 25 | $-0.74 | $-0.14 | ||
| Q4 24 | $-0.30 | $-0.13 | ||
| Q3 24 | $-0.46 | $-0.08 | ||
| Q2 24 | $-0.30 | $-0.14 | ||
| Q1 24 | $-0.54 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $133.9M |
| 总债务越低越好 | — | $671.3M |
| 股东权益账面价值 | $370.1M | $-392.1M |
| 总资产 | $1.1B | $968.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $133.9M | ||
| Q3 25 | $479.2M | $125.3M | ||
| Q2 25 | $370.0M | $107.0M | ||
| Q1 25 | $358.4M | $171.8M | ||
| Q4 24 | $411.3M | $216.4M | ||
| Q3 24 | $396.9M | $115.9M | ||
| Q2 24 | $360.1M | $141.5M | ||
| Q1 24 | $325.9M | $180.9M |
| Q4 25 | — | $671.3M | ||
| Q3 25 | — | $766.5M | ||
| Q2 25 | — | $770.5M | ||
| Q1 25 | — | $765.8M | ||
| Q4 24 | — | $761.3M | ||
| Q3 24 | — | $596.9M | ||
| Q2 24 | — | $597.4M | ||
| Q1 24 | $93.1M | $603.2M |
| Q4 25 | $370.1M | $-392.1M | ||
| Q3 25 | $401.2M | $-374.5M | ||
| Q2 25 | $156.3M | $-347.8M | ||
| Q1 25 | $164.2M | $-288.1M | ||
| Q4 24 | $228.5M | $-202.1M | ||
| Q3 24 | $237.1M | $-117.7M | ||
| Q2 24 | $264.3M | $-72.2M | ||
| Q1 24 | $266.7M | $936.0K |
| Q4 25 | $1.1B | $968.8M | ||
| Q3 25 | $1.1B | $973.0M | ||
| Q2 25 | $821.4M | $1.0B | ||
| Q1 25 | $807.3M | $1.1B | ||
| Q4 24 | $885.1M | $1.2B | ||
| Q3 24 | $901.9M | $1.0B | ||
| Q2 24 | $904.5M | $1.1B | ||
| Q1 24 | $831.9M | $1.2B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | 644.43× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-18.4M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-58.3M |
| 自由现金流率自由现金流/营收 | -7.1% | -31.7% |
| 资本支出强度资本支出/营收 | 0.1% | 21.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-259.9M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $-18.4M | ||
| Q3 25 | $108.5M | $-37.1M | ||
| Q2 25 | $4.4M | $-62.9M | ||
| Q1 25 | $-53.4M | $-47.9M | ||
| Q4 24 | $19.4M | $37.9M | ||
| Q3 24 | $34.1M | $-16.9M | ||
| Q2 24 | $-8.3M | $-25.2M | ||
| Q1 24 | $-133.0M | $-73.8M |
| Q4 25 | $-14.3M | $-58.3M | ||
| Q3 25 | $108.3M | $-60.4M | ||
| Q2 25 | $4.4M | $-78.6M | ||
| Q1 25 | $-53.4M | $-62.6M | ||
| Q4 24 | $19.3M | $-70.2M | ||
| Q3 24 | — | $-21.9M | ||
| Q2 24 | $-8.4M | $-30.8M | ||
| Q1 24 | $-133.3M | $-77.8M |
| Q4 25 | -7.1% | -31.7% | ||
| Q3 25 | 23.6% | -32.6% | ||
| Q2 25 | 2.5% | -41.5% | ||
| Q1 25 | -32.0% | -35.3% | ||
| Q4 24 | 9.1% | -34.3% | ||
| Q3 24 | — | -11.3% | ||
| Q2 24 | -4.2% | -15.7% | ||
| Q1 24 | -77.3% | -39.5% |
| Q4 25 | 0.1% | 21.7% | ||
| Q3 25 | 0.0% | 12.5% | ||
| Q2 25 | 0.0% | 8.3% | ||
| Q1 25 | 0.0% | 8.3% | ||
| Q4 24 | 0.0% | 52.8% | ||
| Q3 24 | 0.0% | 2.6% | ||
| Q2 24 | 0.0% | 2.9% | ||
| Q1 24 | 0.2% | 2.0% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
UP
暂无分部数据
